Eli Lilly and LLY
- Market cap
- $1.3T
- PE
- 46.5×
- 10y median 41.6×
- Forward PE
- 30.9×
- 10y median 28.3×
- Price to sales
- 15.6×
- EV/EBIT
- 35.1×
- Revenue, 12 months
- $86.5B
- +46% on a year ago
- Net margin
- 31.9%
- Free cash flow yield
- n/m
- Q3 FY26 missing
A Superworth story
Lilly's price ran to a new high before its report
Earnings grew into the old premium. The next report tests whether they can carry the new one.
A new high, with no new results
Lilly closed at a new high in late October, more than double its price three years ago. The last month alone added about a tenth. There has been no report since August, so the price moved ahead of fresh numbers. The third quarter comes out on October 29.
Sales more than doubled in three years
Over the last twelve months Lilly sold 79.67 billion dollars of medicine, up about half on the year before. Mounjaro and Zepbound, two brands of one diabetes and obesity drug, tirzepatide, did most of the lifting.
Profit grew far faster than sales
Earnings reached 29.80 dollars a share over the last twelve months, about five times the level three years ago. Margins widened as sales doubled, to near the widest of the last ten years, so profit outran revenue.
So the PE fell back to its old norm
In July 2024 investors paid 140 times earnings, a bet that the drugs would grow into the price. They did. At about 43 times, the PE sits below where it spent most of the last five years, back near its ten-year median and a little above its industry peers.
On sales, the premium is the margin bet
Price to sales, the stock's value over a year of revenue, tells a different story. At about 15 times sales, Lilly costs roughly three times what it did before tirzepatide reached the market in 2022. That premium rests on margins. Lilly now keeps far more of each dollar of sales as profit than it used to, and the premium holds only while margins stay this wide.
Most of the bet rides on one molecule
The fear is concentration and price. Mounjaro and Zepbound made about two thirds of second-quarter sales, and Lilly agreed with the US government to sell Zepbound to Medicare for a fraction of its list price. The hope is the next wave: retatrutide, a newer obesity drug that took off about a fifth of body weight in a late-stage trial and is set to be filed in early 2027.
The price assumes another fast year
At today's price, consensus puts Lilly at about 34 times its next twelve months of adjusted earnings, far above its peers. Part of that is a one-off: Lilly expects a large charge for drug rights it bought in the quarter that ended in September, and counts it in adjusted earnings. The third-quarter report tests whether sales are on track for about 86 billion dollars this year, the middle of Lilly's raised guidance.
What has happened lately
- Eli Lilly, Lilly expects about $4.2 billion of acquired IPR&D charges in the third quarter, about $4.57 a shareLilly counts charges for drug rights it buys in both GAAP and adjusted earnings, so this one-off lowers the quarter that reports on October 29 and lifts the forward PE.
- Eli Lilly, Retatrutide took off up to 20.8% of body weight over 80 weeks in TRIUMPH-2, in adults with obesity and type 2 diabetesLilly's next obesity drug, a triple agonist, also cut A1C by up to 1.6 points. Lilly plans to file it with the FDA in the first quarter of 2027, the next leg the price is counting on.
- SEC, Lilly reports second-quarter revenue of $23.0 billion, up 48%, and raises full-year guidanceThe latest report: Mounjaro made $9.9B and Zepbound $4.9B of the quarter. Revenue guidance rose to $85B-$87B, and the October 29 report tests it.
- Eli Lilly, Lilly and the U.S. government agree to expand access to obesity medicinesMedicare pays $245 a month for Zepbound and Lilly sells it direct from $299, in return for tariff relief. More patients, at a lower price per dose.
Headlines link to the original source.
Brought to you by Superworth
Why a stock is priced where it is, one chart at a time.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $9.4B+28% | $8.8B+26% | $11.3B+36% | $11.4B+20% | $13.5B+45% | $12.7B+45% | $15.6B+38% | $17.6B+54% | $19.3B+43% | $19.8B+56% | $23B+48% | $24.4B+39% | |
| Cost of revenue | $1.8B+16% | $1.7B+3% | $2.2B+20% | $2.2B+17% | $2.4B+34% | $2.2B+33% | $2.4B+13% | $3B+39% | $3.4B+40% | $3.6B+61% | $3.3B+34% | $3.9B+31% |
| Gross profit | $7.6B+32% | $7.1B+33% | $9.1B+40% | $9.3B+21% | $11.1B+47% | $10.5B+48% | $13.1B+44% | $14.6B+57% | $15.9B+43% | $16.2B+54% | $19.7B+50% | $20.5B+40% |
| R&D | $2.6B+28% | $2.5B+27% | $2.7B+15% | $2.7B+14% | $3B+18% | $2.7B+8% | $3.3B+23% | $3.5B+27% | $3.8B+26% | $3.5B+28% | $3.8B+15% | $4.2B+23% |
| SG&A | $1.9B+17% | $2B+12% | $2.1B+10% | $2.1B+16% | $2.4B+26% | $2.5B+26% | $2.8B+30% | $2.7B+31% | $3.1B+29% | $2.9B+19% | $3.4B+25% | $3.1B+14% |
| $2.4B+30% | $2.5B+68% | $3.7B+75% | $1.5B+239% | $5.1B+116% | $3.7B+47% | $6.9B+85% | $7.4B+383% | $8.4B+63% | $8.9B+141% | $9B+31% | $8.6B+17% | |
| Interest expense | $138.2M+65% | $179.6M+75% | $183.6M+53% | $192.7M+55% | $224.7M+63% | $243.7M+36% | $249M+36% | $179.6M−7% | $222.6M−1% | n/a | n/a | n/a |
| Pre-tax income | $2.5B+20% | $2.5B+66% | $3.5B+68% | $1.6B+272% | $5B+101% | $3.5B+36% | $6.8B+93% | $7.2B+355% | $8.3B+64% | $8.8B+156% | $9.2B+36% | $8.4B+16% |
| $319.1M+101% | $293.2M+59% | $550.2M+69% | $618.1M+28% | $628.9M+97% | $696.8M+138% | $1.1B+103% | $1.6B+167% | $1.6B+159% | $1.5B+109% | $2.2B+93% | $2B+19% | |
| Net income | $2.2B+13% | $2.2B+67% | $3B+68% | $970.3M | $4.4B+101% | $2.8B+23% | $5.7B+91% | $5.6B+475% | $6.6B+51% | $7.4B+168% | $7.1B+25% | $6.5B+16% |
| $2.42+13% | $2.48+66% | $3.28+68% | $1.07 | $4.88+102% | $3.06+23% | $6.29+92% | $6.21+480% | $7.39+51% | $8.26+170% | $7.94+26% | $7.22+16% | |
| 904M−0% | 903.8M+0% | 904.2M+0% | 905M+1% | 903.2M−0% | 900.6M−0% | 899.8M−1% | 898.8M−1% | 898M−1% | 895.9M−1% | 893.7M−1% | 893.4M−1% |
Gross profit: 126 periods, Q1 FY95 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: 126 periods, Q1 FY95 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 10 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: 9 periods, Q4 FY95 to Q4 FY08: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 10 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. 3 periods, Q4 FY17 to Q4 FY19: quarter's net income to common over its shares, to the cent.
Diluted shares: 46 periods, Q1 FY95 to Q3 FY12: not printed by the filing, worked out from its own lines. 10 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. 6 periods, Q4 FY13 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $24.4B | $23.7B to $25.8B | $11.07 | $10.48 to $12.13 | 8 |
| Q1 FY27 | $23.4B | $22.9B to $24B | $10.80 | $10.51 to $11.15 | 3 |
| Q2 FY27 | $25.5B | $25B to $26.2B | $12.11 | $11.79 to $12.51 | 1 |
| Q3 FY27 | $26B | $25.5B to $26.6B | $12.41 | $12.08 to $12.82 | 1 |
| Q4 FY27 | $27.1B | $26.5B to $27.8B | $13.28 | $12.93 to $13.71 | 1 |
| Q1 FY28 | $26B | $25.5B to $26.7B | $12.59 | $12.25 to $13.00 | 2 |
| Q2 FY28 | $26.6B | $26.1B to $27.3B | $13.02 | $12.68 to $13.45 | 2 |
| Q3 FY28 | $27.4B | $26.8B to $28B | $13.55 | $13.19 to $13.99 | 2 |
Peers
Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LLYEli Lilly and | $1.3T | 46.5× | 41.6× | 30.9× | 15.6× | +46% | 31.9% |
| JNJJohnson & Johnson | $650.2B | 40.9× | 24.3× | 23.9× | 6.5× | +8% | n/m |
| ABBVAbbVie | $511.6B | 49.8× | 27.9× | 18.3× | 7.7× | +11% | 15.7% |
| MRKMerck | $359.5B | 150× | 25.0× | 17.2× | 5.3× | +5% | 3.6% |
| AMGNAmgen | $252.3B | 29.0× | 21.2× | 19.8× | 6.6× | +9% | 23.0% |
| GILDGilead Sciences | $212.5B | n/m | 18.8× | 19.8× | 6.9× | +7% | −12.5% |
| PFEPfizer | $176B | 40.6× | 15.8× | 11.2× | 2.8× | −0% | 6.8% |
| Peer median | $305.9B | 40.9× | 22.7× | 19.1× | 6.6× | +7% | 6.8% |
Investors who own it
Investors we follow who held Eli Lilly and at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital6.9% of portfoliotrimmed
- Cathie WoodARK Investment Management0.6% of portfolioadded
- Stanley DruckenmillerDuquesne Family Office0.3% of portfolionew
- Ron BaronBaron Capital0.3% of portfolioadded
- Bill NygrenHarris Associates (Oakmark)0.0% of portfoliotrimmed
More on Eli Lilly and
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #9of 53Healthcare stocks with the fastest expected revenue growth
- #7of 34Healthcare stocks with the lowest PEG ratio
- #7of 24Large drugmakers with the fastest earnings growth
- #10of 17Large drugmakers cheapest against their own PE history
Its groups
About
- Chief executive
- Dave Ricks, since 2017Joined 1996, CEO since 2017. Source
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .